Effects of chronic administration of SB203580 (15 and 30 mg/kg, i.p., 2× daily) on cancer-induced spontaneous flinching (A,B) spontaneous guarding (C,D), tactile allodynia (E,F) and limb use (G,H). Time-course analysis indicate a time-dependent decrease in tumor-induced spontaneous flinching (A) guarding (B) and limb use (E), but no change in tactile hypersensitivity (G). *indicates significant difference from vehicle treated group. Analysis on day 13 demonstrates decreased flinching (B), guarding (D) and limb use (F) in cancer mice treated with 15 as well as 30 mg/kg SB2035580. Chronic treatment with SB203580 failed to alter tactile hypersensitivity at either dose. *indicates significant difference from cancer vehicle group (p < 0.05). All graphs show means ± SEM. n = 6-8.